Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01109238 · ClinicalTrials.gov registry record
A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma
A clinical trial, sponsored by Giselle Sholler.
- Completed
- Registry status
- 5
- Enrollment target
NCT01109238 is a clinical trial that has completed, run by Giselle Sholler. The registered enrollment target is 5 participants.
The verdict
NCT01109238 has completed, sponsored by Giselle Sholler.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
Study Summary
The investigators are studying new ways to make treatment decisions for these types of cancer. Technologies at the Van Andel Research Institute (VARI) are available to determine a tumor's molecular makeup (gene expression profile). This technology (called "Xenobase") is being used to discover new ways to understand cancers and potentially predict the best treatments for patients with cancer. The researchers at VARI have filed a patent on the Xenobase and the specific network analysis method that the investigators will be using as part of this study. A specimen obtained from the tumor during a recent surgical, biopsy, or bone marrow procedure will be sent to the Van Andel Research Institute. Researchers will attempt to identify the molecular makeup within the specimen, as well as in blood and urine samples in patients with aggressive and/or refractory cancer. This additional testing is different than the routine tests currently performed at the hospital for the evaluation of cancer. The goals of this part of the study are: To determine if the investigators tumor board committee (at minimum a panel of 3 oncologists and 1 pharmacist) can use patient specific cancer cells to make real-time treatment decision using patient specific genetic information, and predicted therapies generated in the Xenobase report.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-04 |
| Est. Completion | 2010-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01109238
The ClinicalTrials.gov registry entry for NCT01109238 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Giselle Sholler, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01109238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01109238 about?
NCT01109238 is a clinical study titled "A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma". The investigators are studying new ways to make treatment decisions for these types of cancer. Technologies at the Van Andel Research Institute (VARI) are available to determine a tumor's molecular makeup (gene expression profile). This technology (called "Xenobase") is being used to discover new wa...
What is the current status of trial NCT01109238?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2010-04. Estimated completion is 2010-07.
Who is sponsoring clinical trial NCT01109238?
This trial is sponsored by Giselle Sholler, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.